Kim Chi

Dr. Kim Nguyen Chi is a medical oncologist and chair of the Genitourinary Tumour Group for the BC Cancer Agency, Vancouver, Canada. He is also an Associate Professor of Medicine at the University of British Columbia, and the medical director for Clinical Trials at the Vancouver Cancer Centre.

Dr. Chi’s research is in the area of genitourinary cancers with a focus in prostate cancer and investigational new drugs.  This includes phase I, II and III clinical trials, therapeutic use of antisense oligonucleotides and small molecules, neoadjuvant studies and mechanisms of treatment resistance. He holds peer-reviewed grant funding from the Canada Institutes of Health Research (CIHR), National Cancer Institute of Canada (NCIC)/Canadian Cancer Society (CCS), the US Department of Defense, and the Prostate Cancer Research Foundation of Canada. Nationally and internationally, Dr. Chi has led a number of multi-centre phase I, II and III clinical trials. He is an author on more than 70 peer-reviewed publications in, among others, the Journal of Clinical Oncology, Journal of the National Cancer Institute, and the New England Journal of Medicine.

Dr. Chi is an executive committee member of the Genitourinary Disease Site for the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG)/Canadian Uro-Onology Group, and the chair of the sub-site Advanced Prostate Group. This committee and group is responsible for developing, undertaking, organizing and coordinating the genitourinary and prostate cancer trials undertaken by investigators at a national cooperative group level.  He is also an executive committee member and chair of the Investigational New Drug Site for the NCIC-CTG, which is responsible for developing, undertaking, organizing and coordinating early phase I/II trials across the NCIC-CTG disease sites. Dr. Chi is also a member of the Prostate Task Force Committee for the US NCI CTEP, which vets trial concepts being considered for activation through US cooperative groups.